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Abstract The story of hepatitis C virus (HCV) therapy is
about to add one of its biggest chapters. From the
serendipitous beginnings in the 1980s when investigators
noted that interferon improves liver enzymes in non-A,
non-B hepatitis, to the discovery and naming of the
hepatitis virus, to the addition of ribavirin, to the pegylation
of interferon, and now to the first direct-acting antivirals
(DAA), the history of HCV is an intriguing one that
continues to unfold. Along with the first DAAs, other
important findings have helped explain long-observed
differences between various ethnic groups, as well as new
predictive information that can be gleaned from some of the
observed adverse events.
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Introduction
Big changes are coming in the field of hepatitis C. In fact,
the soon-to-arrive direct-acting antiviral (DAA) therapies
will be the biggest advance in the field since the addition of
ribavirin to interferon and the pegylation of interferon [1–
5]. Addition of an oral antiviral to the pegylated interferon/
ribavirin (PEG/RBV) backbone could nearly double the
sustained virologic response (SVR) rate of genotype 1
disease. The first two DAAs will be the linear serine
protease inhibitors, telaprevir (TVR) and boceprevir (BOC).
These two compounds have more similarities than differ-
ences and will likely be widely used when available in
2011. Soon to follow are other compounds, and perhaps
combinations of DAAs with different mechanisms of
action.
The hepatitis C virus has genomic heterogeneity, and
multiple genotypes and subtypes exist. Of the six predom-
inant genotypes, hepatitis C virus (HCV) genotype 1 is the
most common strain in the United States, Europe, and
Japan, and is the most difficult to eradicate [6]. From
dismal early results, with 6 months of interferon mono-
therapy curing fewer than 5% of patients, the addition of
ribavirin and prolongation to 48 weeks increased this rate
more than fivefold to 25% to 30%. [3] The pegylation of
interferon led to overall improvement in efficacy to 40% [4,
5]. This combination has been the standard of care for most
of the past decade. The 3000-patient, multicenter Individ-
ualized Dosing Efficacy versus Flat Dosing to Assess
Optimal PegInterferon Therapy (IDEAL) trial was the
largest study of treatment-naïve patients with HCV geno-
type 1 disease, and revealed that pegylated interferon-α2a
and 2b, when combined with ribavirin, have comparable
efficacy and adverse events [7].
The discovery of DAAs for the treatment of HIV set the
stage for the development of similar classes of compounds
for HCV [8]. The development of protease inhibitors was
hindered by challenges related to binding inefficiencies and
toxicity; the proof of concept turning point came with the
Boehringer Ingelheim (Ingelheim am Rhein, Germany)
compound 2061, which showed that over a 3-day course,
viral declines of greater than 4 log could be achieved [9].
Although this compound did not see further development
because of the risk of cardiac toxicity, it was catalytic in the
development of other similar compounds.
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coming. Duration of therapy will be based on early viral
responses. Baseline predictors of response have always
been important in determining likelihood of response, but
new genetic determinants will advance this field as well.
Finally, the promise of an interferon-free regimen draws
ever closer and will be the focus of many upcoming clinical
trials in the next few years.
Protease Inhibitors
The serine protease NS3-NS4A is used by HCV for post-
translational processing and viral replication. This was the
first successful target of drug development in HCV.
Protease inhibitors have been shown to be potent inhibitors
of viral replication, but when used as monotherapy,
resistance quickly develops [10]. Hence, the addition of
this class of compound to an interferon/ribavirin-containing
regimen is the current development paradigm. This devel-
opment does not preclude the use of this class in future
interferon-sparing regimens, as long as other compounds
can cover emerging resistant strains.
Boceprevir
The first two protease inhibitors that have now completed
phase 3 trials are boceprevir and telaprevir, both linear
compounds taken orally three times per day and used for
HCV genotype 1. Boceprevir (SCH-503034; BOC) in the
phase 2b trial (HCV Serine Protease Inhibitor Therapy 1
[SPRINT 1]) of 595 patients was evaluated as triple therapy
with peginterferon alfa 2b (PEG2b) and ribavirin (RBV) for
28–48 weeks. A unique lead-in strategy of 4 weeks of
PEG2b/RBV was also evaluated followed by triple therapy
for 24–44 weeks (discussed in detail below). This lead-in
was found to lower viral breakthrough and was adopted for
the phase 3 trials. The SVR rates in the phase 2b trial
treating previously untreated patients ranged from 55% to
75% [11]. This study also assessed a low-dose ribavirin
arm, which yielded a lower SVR than control, and a higher
viral breakthrough and relapse. Hence, the importance of
ribavirin dosing appears to be paramount even in the setting
of a protease inhibitor. In this study, patients received either
24 or 44 weeks of BOC, and it appeared the longer duration
was superior. However, the use of 24 weeks of BOC
followed by another 24 weeks of only PEG/RBV was to be
assessed in the phase 3 trial.
The phase 3 trial, called SPRINT 2 (Fig. 1), assessed
about 1,100 patients in two separate cohorts, the second
cohort being exclusively patients of African descent. In
cohort 1, 68% of patients achieved SVR whereas 53% of
black patients (cohort 2) achieved SVR with triple therapy
using a 4-week lead in followed by 44 weeks of triple
therapy. Using a response-guided treatment regimen
allowed about half of the patients to be treated with a 4-
week lead-in followed by 24 weeks for triple therapy with
PEG/RBV/BOC. This led to SVR rates of 67% and 42% in
non-blacks and blacks, compared to controls of 40% and
23% (P=0.004 and P=0.044), respectively [12]. From these
data, it appears that BOC can be used for a 24-week period,
and the total duration of PEG/RBV would be 28 weeks for
patients who become viral negative by week 8 and remain
so until week 24. Conversely, patients who become viral
negative between weeks 8 and 24 would receive 24 weeks
of BOC, but 48 weeks of PEG/RBV. This response-guided
approach allows the minimization of treatment duration, but
maximizes efficacy. The rate of anemia with BOC-
containing regimens is almost double that of PEG/RBV,
but rarely leads to treatment discontinuation.
Fig. 1 Serine Protease Inhibitor Therapy (SPRINT) 2 and A New
Direction in HCV Care: A Study of Treatment-naïve Hepatitis C
Patients with Telaprevir (ADVANCE): design of the boceprevir
(BOC) and telaprevir (TVR) phase 3 trials in treatment-naïve hepatitis
C virus (HCV) genotype 1 patients. eRVR—extended rapid viral
response; PR—pegylated interferon and ribavirin; TW8—treatment
week 8
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the Retreatment with HCV Serine Protease Inhibitor
Boceprevir and PEGINTRON/REBETOL 2 (RESPOND
2) trial. The phase 2 study that preceded this study did not
use the ultimate dose of boceprevir with full-dose RBV, and
led to SVR rates of only 14%. With appropriate dosing of
boceprevir in the 404-patient RESPOND 2 trial, the SVR
rates were 66% in the 48-week arm, and 59% in the
response-guided arm, both significantly better than the
control of 21% [12]. Although the study intended to
exclude the so-called “null” responder patient, a large
percentage of patients enrolled appear to fit that description.
In fact, 25% of the patients achieved less than a 1-log viral
decline at the end of the lead-in period, indicating that they
had poor interferon response. Anemia occurred in up to
47% of patients on BOC-containing arms and in 20% of
controls. Interestingly, discontinuations from anemia only
occurred in 2% of patients, indicating that anemia may not
be a treatment-limiting adverse event.
Lead-in Strategy
One of the unique features of the boceprevir development
strategy was to use a 4-week lead-in of PEG/RBV prior to
initiating boceprevir. The original premise was to lower viral
load and theoretically decrease viral breakthrough and
resistance. This premise was borne out in the SPRINT 1 trial.
Additionally, other potential utilities of such a paradigm have
come to light. Patients who achieve rapid viral response
(RVR) at the end of the lead-in period are known to have high
SVR rates to PEG/RBV, even with a shortened 24-week
duration of therapy [13, 14]. Although RVR occurs in only
10% of US patients, it occurs in up to 26% of European
patients [7, 15], leading to speculation that this lead-in
paradigm could be used by health care plans to spare DAA
therapy in this group, which has a high likelihood of viral
clearance with current standard therapy. Conversely, patients
who are minimally responsive to PEG/RBV in the lead-in
have relatively low SVR rates in the mid-30% range. These
patients may require more diligent monitoring for resistance
and may benefit from more effective future therapies that
increase response rates and minimize resistance. Finally, the
lead-in tests the patient’s compliance and tolerance to PEG/
RBV prior to committing to the increased adverse event
profile associated with DAAs. Patients who cannot tolerate
PEG/RBV should not be given a DAA.
Telaprevir
Telaprevir(VX-950;TVR)isanotherserineproteaseinhibitor
that has completed its phase 3 trial (ADVANCE; A New
DirectioninHCVCare: AStudyofTreatment-naïveHepatitis
CPatientswithTelaprevir)inpreviouslyuntreatedgenotype1
patients, yielding a 75% SVR compared to a control of 44%.
The response-guided therapy regimen of this study will be the
preferred treatment paradigm, with over half of patients
receiving 12 weeks of TVR and 24 weeks of PEG/RBV, and
the others 48 weeks of PEG/RBV. Although this study also
tested 8-week duration of TVR, it had a lower SVR of 69%
and will likely not be the preferred regimen [16]. The two
phase 2b studies, called Protease Inhibition for Viral
Evaluation 1 and 2 (PROVE 1 and 2), were conducted in
the United States and Europe, respectively. The SVR rates
were 61% to 69%; several different arms were studied,
including a short-duration therapy and a ribavirin-free arm.
The trial design of the phase 3 study was different in that a
response-guided approach was used. Patients who were
viral-negative at weeks 4 and 12, the so-called extended
RVR (eRVR), received a total duration of 12 weeks of TVR
with 24 weeks of PEG/RBV. Patients who did not achieve
eRVR received a total of 48 weeks of PEG/RBV. More than
half of the patients were eligible for the shorter duration.
This result was validated in the Illustrating the Effects of
Combination Therapy with Telaprevir (ILLUMINATE) trial;
this 540-patient trial did not have a control arm, but
randomly assigned patients with eRVR to a total duration
of therapy of 24 versus 48 weeks with 12 weeks of TVR.
This trial revealed that the overall SVR in the study was
72%, but patients meeting eRVR did not benefit from a total
duration of 48 weeks of PEG/RBV, with SVR rates of 92
and 88%, respectively, when eRVR was achieved [17].
The phase 2b trial assessing previously treated PEG/
RBV patients, called the PROVE 3 study, tested several
treatment durations. Based on the findings of that trial, it
was decided that a total duration of 48 weeks of PEG/
RBV with 12 weeks of TVR would be the paradigm for
previously treated patients moving into the phase 3 trial.
Hence, all arms of the phase 3 Re-treatment of Patients
with Telaprevir-based Regimen to Optimize Outcomes
(REALIZE) trial were 48 weeks in duration. One of the
arms had the experimental 4-week lead-in of PEG/RBV
preceding 12 weeks of triple therapy, followed by
32 weeks of PEG/RBV. The results of that arm were
66%, with 64% in the 48-week arm, and 17% in the
control arm. In a pooled analysis of both study arms,
relapsers had the highest SVR at 86% (24% control),
followed by those who had a partial response to previous
treatment at 57% (15% control), and finally, null
responders at 31% (5% control) [18].
Similarities and Differences Between Boceprevir
and Telaprevir
Based on the phase 2 data, it is clear that ribavirin plays a
critical role in the treatment regimen of both protease
74 Curr Gastroenterol Rep (2011) 13:72–77inhibitors. Indeed, in the RBV-free or low-dose RBV arms
of PROVE 2 and SPRINT 1, respectively, SVR rate was
only 36% compared to controls of 46% and 38%. Hence,
maintenance of optimal ribavirin dosing remains an
important treatment goal with both regimens. This may be
an issue given the higher rate of anemia seen in these
studies. Anemia is a class effect of linear protease
inhibitors, but is more common with BOC compared to
TVR. Only 23% of patients in the SPRINT 1 trial
maintained a hemoglobin above 11 g/dL, compared to
35% of patients in PROVE 1. In these two studies, 27% and
23% of patients had hemoglobin levels that fell below
9.5 g/dL with BOC- and TVR-based therapies, respectively
[11, 19].
The major unique adverse event related to BOC appears
to be dysgeusia (32%; 23% higher than control). About one
third of patients experience dysgeusia, though it was not
treatment limiting (Table 1). The adverse events that appear
to be more common with TVR are rash and pruritus.
Although 61% of patients had some degree of rash in the
PROVE 1 study (20% higher than control), only a minority
had to discontinue for this reason. Similarly, 48% had
pruritus (25% higher than control) but it was not a
treatment-limiting adverse event (Table 1). Discontinuation
for rash occurs in 5% to 7% of patients, so it is likely not
going to be a major limitation to treatment. With all of these
adverse events, provider experience will be a major
determinant of maintaining patients on treatment. Appro-
priate symptomatic treatment for these patient complaints
will be a major part of the overall management, and will
require diligence on the part of the health care provider
team.
Treatment Regimen Differences
Based on the phase 3 study designs for BOC and TVR, it is
likely that response-guided therapy will be the new
paradigm for treatment-naïve patients. However, the para-
digms are quite different. The BOC treatment will be a 4-
week lead-in with PEG/RBV followed by 24 weeks of
PEG/RBV/BOC and no further treatment for patients who
became negative by week 8 and remain so until week 24.
Patients who had detectable virus at any point between
weeks 8 and 24, will stop BOC at week 28, but will
continue PEG/RBV until week 48. Hence, all patients will
have 24 weeks of BOC, and rapid responders will have
total treatment duration of 28 weeks, whereas slow
responders will have an extra 20-week extension of PEG/
RBV. The treatment-experienced population will also likely
have response-guided therapy with a lead-in and 36 weeks
of PEG/RBV/BOC, with or without an additional 12 weeks
of PEG/RBV for those patients who had detectable virus at
week 8. Previously treated patients with detectable virus at
week 12 will discontinue therapy for futility.
The TVR response-guided protocol for treatment-naïve
patients will require viral negativity at weeks 4 and 12 for
the total treatment duration to be 24 weeks, with TVR
given over the first 12 weeks only. If patients do not have
undetectable virus at both 4- and 12-week time points, they
will require a total duration of 48 weeks of PEG/RBV. The
paradigm for treatment-experienced patients will not be
response-guided based on the design of the REALIZE trial.
Patients will receive 12 weeks of TVR and 48 weeks of
PEG/RBV.
In both the BOC and TVR phase 3 trials, the SVR in
patients with a poor response to interferon, whether it was
by historical assessment of 12-week lab values from
referring doctors’ records, or lack of a 1-log decline at the
end of the lead-in period, was very low, ranging from 29%
to 34%. This population is perhaps not ideally served by
either of these compounds, and further assessment of more
potent compounds or more novel regimens is warranted.
Until such time, it is likely that patients with null responses
to interferon will be retreated with BOC and TVR, but
retreatment should be done with great care, because viral
breakthrough and relapse rates are high.
In distinction to this population, treatment-naïve patients,
partial responders, and relapsers appear to have much better
response rates and clearly are the prime groups to target for
treatment. Patients with HIV coinfection, pre-transplant
patients with low platelet counts, decompensated liver
Table 1 Common adverse events in phase 2 studies of boceprevir and telaprevir*
Adverse event, % SPRINT 1 PROVE 1 PROVE 2
Control BOC Control TVR Control TVR
Rash 37 45 41 61 35 49
Pruritus 15 22 23 48 35 63
Dysgeusia 9 32 0 0 0 0
BOC boceprevir, PROVE Protease Inhibition for Viral Evaluation, SPRINT Hepatitis C Virus Serine Protease Inhibitor Therapy, TVR telaprevir;
*Anemia discussed in more detail in text
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yet to be studied. Although these patients represent very
important subsets of the HCV population, treatment of
these groups will have to await study results prior to any
recommendations.
The study designs of BOC and TVR are quite different.
The differences of these new treatment paradigms will
require clinicians to apply different laboratory monitoring
strategies based on the regimen being used. Although a
learning curve is inevitable, the concept of individualization
of therapy is beneficial for the patient and ultimately is
designed to prevent over- and under-treatment. There are no
head-to-head comparisons of these two compounds, but
both BOC and TVR are being evaluated with both
pegylated interferon alfa-2a and 2b to determine if the
interferons can be used interchangeably with either drug.
Other Compounds in Development
No other HCV DAA compounds are in phase 3 develop-
ment yet. Of the several other protease compounds, the
Tibotec (Mechelen, Belgium) TMC 435 compound has
shown the most promise based on daily dosing and a good
safety profile. The polymerase inhibitors are more numer-
ous and are beyond the scope of this article to review. They
have been somewhat difficult to develop because of
toxicity, but the hope is that in combination with a protease
inhibitor, the lack of cross resistance and possible syner-
gistic antiviral activity will allow for a more robust regimen
when added to the PEG/RBV backbone. Along the same
lines, the NS5A inhibitors are being evaluated as members
of multi-compound cocktails. The Bristol-Myers Squibb
(New York, NY) compound BMS790052 is currently being
studied; if effective and safe, it will allow the further
development of this interesting class of compound [20].
Other agents being evaluated (e.g., cyclophilin inhib-
itors, nitazoxanide, and silymarin) will likely not have
major roles in this treatment arena. The need to find novel
targets will drive further development, particularly to
address the future BOC and TVR treatment failures, who
will need a more complex regimen [20].
Other Important Developments
It has long been known that anemia is one of the major side
effects of HCV therapy. What has recently been appreciated
is the correlation with anemia and SVR. Of the 3,070
patients in the IDEAL trial, 28.6% (N=865) developed
anemia (hemoglobin <10 g/dL). About half of these
patients received an erythropoiesis-stimulating agent
(ESA). When anemia occurred within 8 weeks of treatment
initiation, the use of ESA was associated with fewer patient
discontinuations, and hence enhanced SVR (45.2% vs.
25.9%, P<0.001). Similarly, in patients who had greater
than a 3 g/dL decline in hemoglobin, SVR was more likely
to occur (43.7% vs. 29.9%, P<0.001) [21￿]. The likely
explanation is that these individuals have an adequate
exposure to ribavirin. However, it has also been shown that
genetic polymorphisms in inosine triphosphatase deficiency
are protective against hemolytic anemia [22￿]. Hence,
some patients without anemia will also achieve sustained
response. The association of anemia to SVR in the setting
of DAAs has yet to be fully evaluated.
The identification of a single-nucleotide polymorphism
(SNP), rs12979860 on chromosome 19, near the gene that
encodes interleukin (IL)-28B was a major discovery that
came out of the IDEAL trial. More than half of the 3,070
patients consented to genomic testing, and identification of
this association with SVR has explained at least some of the
genetic differences previously noted in interferon response
rates. The favorable homozygous CC haplotype is associ-
ated with more than a twofold increase in SVR compared to
other haplotypes, such as CT or TT. Interestingly, the
prevalence of the CC haplotype is proportional to the SVR
rates seen in various ethnicities: highest in Asians, lowest in
African ethnicities. The favorable polymorphism leads to
early viral decline and hence, higher SVR. In patients with
the CC genotype, RVR was achieved more frequently.
However, even when it was not achieved, SVR was more
likely to occur in CC patients by a factor of two. As a
baseline predictor of response, in multivariable regression
analysis, IL-28B haplotype was the strongest forecaster of
SVR (OR=5.2; 4.1–6.7, 95% CI, P<0.0001). Although
RVR has a higher positive predictive value, it is an on-
treatment variable, and not of utility prior to treatment.
Patients with CC genotype have a high probability of
response to the current standard of care therapy. The utility
of DAAs in this population may be to shorten therapy to
6 months, perhaps even shorter. Data on IL-28B haplotypes
were collected in some DAA trials, and further assessment
on the utility in the setting of these new therapies has yet to
be determined. The test is now clinically available through
LabCorp (Burlington, NC) on a buccal swab or whole-
blood specimen (test number 480630; IL28B polymor-
phism genotype by RT-PCR) [23￿]. As more data emerge
from the ongoing DAA trials, the utility of this test will be
fully appreciated, and it is likely that it will be a part of the
standard assessment of genotype 1 patients in particular.
Conclusions
The upcoming change in HCV genotype 1 therapy will be
the most important advance in more than a decade. The first
76 Curr Gastroenterol Rep (2011) 13:72–77anticipated DAAs to be approved will be boceprevir and
telaprevir. Both have shown efficacy over current standard
therapy and appear to be effective in naïve and treatment-
experienced patients. The complexity of these regimens and
the added adverse events will require a new level of interest
and diligence by health care providers, and understanding
by patients who may have expected a simpler treatment
regimen. However, the potential benefits are immense, and
a much larger percentage of patients should be able to enjoy
sustained viral clearance, altering the natural history of the
disease in many. These big changes are likely only the
beginning of many more changes to come, including other
novel compounds and perhaps even all-oral therapies in
some patients. Undoubtedly, 2011 will become a pivotal
and historic year in the story of hepatitis C treatment.
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